当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

Abstract：

BACKGROUND:Limited data are available on the efficacy and safety of antiviral therapy in geriatric patients with chronic hepatitis C virus (HCV) infection. AIM:To evaluate the efficacy and safety of pegylated interferon (pegIFN) plus ribavirin (RBV) therapy in geriatric HCV-infected patients. METHODS:Ninety-one geriatric patients (age ≥65 years; the elderly group) with HCV infection and 91 gender- and HCV genotype-matched middle-aged patients (age 50-64 years; the younger group) were assigned to receive weekly pegIFN injection plus weight-based oral RBV for 24 weeks. The on- and off-treatment virological responses were evaluated for treatment efficacy. RESULTS:In intention-to-treat analysis, the sustained virological response (SVR) rate was substantially decreased in the elderly patients (elderly group vs. younger group, 40.7% vs. 61.5%, respectively; P = 0.005). The SVR rate was significantly lower in geriatric patients than in middle-aged patients with HCV genotype non-1 (54.3% vs. 82.9%; P = 0.01), but the difference was not significant with HCV genotype 1 (32.1% vs. 48.2%; P = 0.083). Furthermore, the older patients infected with HCV genotype non-1 who achieved a rapid virological response had a similar SVR rate to that of the younger patients. The withdrawal rate was 13.2% in the elderly group and 7.7% in the younger group. CONCLUSIONS:Compared with middle-aged patients, the therapeutic efficacy of pegylated interferon plus ribavirin therapy is lower in hepatitis C virus-infected geriatric patients with an acceptable withdrawal rate. Considering prolonged lifespan in geriatric patients, we recommend treating geriatric hepatitis C virus-infected patients who have significant hepatic fibrosis and no other health problems.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Hu CC,Lin CL,Kuo YL,Chien CH,Chen SW,Yen CL,Lin CY,Chien RN

doi

10.1111/apt.12112

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

81-90

issue

1

eissn

0269-2813

issn

1365-2036

journal_volume

37

pub_type

杂志文章

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

    abstract：BACKGROUND:Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy. AIM:The evidence supporting the use of therapeutic drug monitoring (TDM)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12407

    authors： Khanna R,Sattin BD,Afif W,Benchimol EI,Bernard EJ,Bitton A,Bressler B,Fedorak RN,Ghosh S,Greenberg GR,Marshall JK,Panaccione R,Seidman EG,Silverberg MS,Steinhart AH,Sy R,Van Assche G,Walters TD,Sandborn WJ,Feagan BG

    更新日期：2013-09-01 00:00:00

  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract：BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2007.03583.x

    authors： Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期：2008-02-15 00:00:00

  • Depression in cirrhosis - a prospective evaluation of the prevalence, predictors and development of a screening nomogram.

    abstract：BACKGROUND:Depression is associated with substantial morbidity and mortality in cirrhosis, but is underdiagnosed and undertreated. AIMS:Using the Mini International Neuropsychiatric Interview (MINI) as a gold-standard, to determine prevalence, predictors, and outcomes of depression, and to develop a screening nomogram...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15068

    authors： Buganza-Torio E,Mitchell N,Abraldes JG,Thomas L,Ma M,Bailey RJ,Tandon P

    更新日期：2019-01-01 00:00:00

  • Systematic review: worldwide variation in the frequency of coeliac disease and changes over time.

    abstract：BACKGROUND:Coeliac disease (CD), originally thought to be largely confined to Northern Europe and Australasia and uncommon in North America and the Middle East, is now recognised to be equally common in all these countries. It is still thought to be rare in the Orient and Sub-Saharan Africa. AIM:To assess geographical...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12373

    authors： Kang JY,Kang AH,Green A,Gwee KA,Ho KY

    更新日期：2013-08-01 00:00:00

  • The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.

    abstract：:Beta adrenoreceptor blocking drugs have been used for the prevention of haemorrhage from oesophageal varices. However, it is possible that these agents, by virtue of their effects on hepatic blood flow, may impair liver function and precipitate hepatic encephalopathy. We have therefore studied the effect of the beta b...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1988.tb00681.x

    authors： Dunk AA,Moore J,Symon A,Dickie A,Sinclair TS,Mowat NA,Brunt PW

    更新日期：1988-04-01 00:00:00

  • Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.

    abstract：BACKGROUND:Infliximab reduces mucosal inflammation in some, but not all, patients with Crohn's disease. AIM:To monitor clinical data and changes in mucosal cytokine levels after infliximab treatment to identify differences between responders and non-responders. METHODS:Twenty-six patients with fistulating Crohn's dis...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01487.x

    authors： Agnholt J,Dahlerup JF,Buntzen S,Tøttrup A,Nielsen SL,Lundorf E

    更新日期：2003-03-01 00:00:00

  • The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study.

    abstract：BACKGROUND:Eosinophilic oesophagitis (EoE) has evolved from a supposedly rare entity to one whose incidence rates are approaching that of inflammatory bowel disease. The factors responsible for this apparent increase in the incidence remain obscure. AIM:To assess various endoscopist and pathologist factors that might ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12053

    authors： Syed AA,Andrews CN,Shaffer E,Urbanski SJ,Beck P,Storr M

    更新日期：2012-11-01 00:00:00

  • Review article: the management of autoimmune hepatitis beyond consensus guidelines.

    abstract：BACKGROUND:Consensus guidelines aid in the diagnosis and management of autoimmune hepatitis, but they are frequently based on low-quality clinical evidence, conflicting experiences and divergent opinions. Recommendations may be weak, discrepant or non-existent at critical decision points. AIMS:To identify the decision...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12381

    authors： Czaja AJ

    更新日期：2013-08-01 00:00:00

  • Review article: Helicobacter pylori and nonulcer dyspepsia.

    abstract：:Although up to 50% of patients diagnosed with nonulcer dyspepsia (NUD) have Helicobacter pylori infection and underlying chronic gastritis, it remains controversial whether any causal relationship exists. The results of worldwide epidemiological studies have been unconvincing. No clear-cut link has been documented bet...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2002.0160s1058.x

    authors： Talley NJ,Quan C

    更新日期：2002-03-01 00:00:00

  • The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury.

    abstract：BACKGROUND:Drug-induced liver injury may be immunologically mediated or metabolically induced. Peripheral eosinophilia and liver eosinophilia in suspected drug-induced liver injury generally supports the role of drug aetiology. AIM:To assess the importance of eosinophilia and hepatic necrosis on outcome in patients wi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2007.03330.x

    authors： Björnsson E,Kalaitzakis E,Olsson R

    更新日期：2007-06-15 00:00:00

  • Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.

    abstract：BACKGROUND:The success of eradication therapy for Helicobacter pylori might be affected by the age of patients. AIM:To investigate whether disposition of drugs commonly used for H. pylori eradication is age-dependent. METHODS:Trough steady state serum levels of lansoprazole or ranitidine, amoxycillin, clarithromycin ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2000.00756.x

    authors： Ammon S,Treiber G,Kees F,Klotz U

    更新日期：2000-06-01 00:00:00

  • The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site.

    abstract：BACKGROUND:The incidence rates of gastric and oesophageal adenocarcinoma are changing significantly, but little is known about specific sub-sites. AIM:To use a population-based approach to describe the trends in the site-specific incidence of oesophageal and gastric adenocarcinoma. METHODS:Using the Rochester Epidemi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.03229.x

    authors： Crane SJ,Richard Locke G 3rd,Harmsen WS,Diehl NN,Zinsmeister AR,Joseph Melton L 3rd,Romero Y,Talley NJ

    更新日期：2007-02-15 00:00:00

  • Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

    abstract：BACKGROUND:Proton pump inhibitors including omeprazole and lansoprazole inhibit gastric acid secretion by selectively and non-competitively inactivating the H+, K+ ATPase molecules of the parietal cell, but possibly only those that are actively secreting acid. This might imply that stimulation of acid secretion by a me...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00829.x

    authors： Hatlebakk JG,Katz PO,Camacho-Lobato L,Castell DO

    更新日期：2000-10-01 00:00:00

  • Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association.

    abstract：BACKGROUND:Population data supporting an association between the autoimmune cholestatic liver diseases, primary biliary cirrhosis and primary sclerosing cholangitis and coeliac disease, is limited and at times contradictory. AIM:To explore the relationship between coeliac disease and both primary biliary cirrhosis and...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2005.02328.x

    authors： Lawson A,West J,Aithal GP,Logan RF

    更新日期：2005-02-15 00:00:00

  • Determinants of compliance with colonoscopy in patients with adenomatous colon polyps in a veteran population.

    abstract：AIM:To determine factors affecting compliance of a follow-up colonoscopy in patients with previously diagnosed adenomatous colon polyps. METHODS:A retrospective review was performed on patients with adenomatous polyps excised between January and December 1998. Twenty-nine clinical factors were assessed in patients gro...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.03176.x

    authors： Siddiqui AA,Patel A,Huerta S

    更新日期：2006-12-01 00:00:00

  • Review article: visceral hypersensitivity.

    abstract：:Visceral hypersensitivity is highly prevalent in all functional bowel disorders. Most also demonstrate wider patterns of somatic referral of intestinal pain or discomfort. This hypersensitivity may explain the symptoms as the sensitive gut can be more easily provoked by normal or abnormal motor events in the gut. Visc...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.01447.x

    authors： Mertz H

    更新日期：2003-03-01 00:00:00

  • Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome.

    abstract：BACKGROUND:Budd-Chiari syndrome (BCS) is a rare but fatal disease caused by obstruction in the hepatic venous outflow tract. AIM:To provide an update of the pathophysiology, aetiology, diagnosis, management and follow-up of BCS. METHODS:Analysis of recent literature by using Medline, PubMed and EMBASE databases. RES...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.15149

    authors： Khan F,Armstrong MJ,Mehrzad H,Chen F,Neil D,Brown R,Cain O,Tripathi D

    更新日期：2019-04-01 00:00:00

  • Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats.

    abstract：BACKGROUND AND AIM:It has been suggested that CN (calcineurin, protein phosphatase-2B) regulates signal transduction, particularly in various secretory cells. In this study, we examined whether CN plays a role in stimulus-secretion coupling of gastric parietal cells. MATERIALS AND METHODS:Localization of CN in gastric...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.16.s2.7.x

    authors： Itoh S,Otaka M,Odashima M,Zeniya A,Okuyama A,Jin M,Otani S,Iwabuchi A,Sasahara H,Masamune O,Watanabe S

    更新日期：2002-04-01 00:00:00

  • Systematic review: sphincter of Oddi dysfunction--non-invasive diagnostic methods and long-term outcome after endoscopic sphincterotomy.

    abstract：BACKGROUND:Sphincter of Oddi dysfunction is a benign, functional gastrointestinal disorder for which invasive endoscopic therapy with potential complications is often recommended. AIMS:To review the available evidence regarding the diagnostic accuracy of non-invasive methods that have been used to establish the diagno...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02971.x

    authors： Sgouros SN,Pereira SP

    更新日期：2006-07-15 00:00:00

  • Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

    abstract：:Alginate-based raft-forming formulations have been marketed word-wide for over 30 years under various brand names, including Gaviscon. They are used for the symptomatic treatment of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of g...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2000.00759.x

    authors： Mandel KG,Daggy BP,Brodie DA,Jacoby HI

    更新日期：2000-06-01 00:00:00

  • Review article: 'true' re-infection of Helicobacter pylori after successful eradication--worldwide annual rates, risk factors and clinical implications.

    abstract：BACKGROUND:The incidence of 'true' re-infection with Helicobacter pylori after successful eradication remains uncertain. AIM:To determine the worldwide rates, risk factors and clinical implications of 'true' re-infection of Helicobacter pylori. 'True' re-infection of H. pylori is defined as the situation where tests f...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2008.03873.x

    authors： Zhang YY,Xia HH,Zhuang ZH,Zhong J

    更新日期：2009-01-01 00:00:00

  • Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis.

    abstract：BACKGROUND:Studies on the use of low-dose proton pump inhibitor for the maintenance therapy of gastro-oesophageal reflux disease have shown that it might be comparable with standard-dose proton pump inhibitor treatment and superior to standard-dose histamine-2 receptor antagonist therapy. AIM:To compare the impact of ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01526.x

    authors： You JH,Lee AC,Wong SC,Chan FK

    更新日期：2003-03-15 00:00:00

  • Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection.

    abstract：:A long-term cure is now possible in more than 30% of selected patients with Zollinger-Ellison syndrome who undergo gastrinoma resection. The need, however, for continued gastric acid antisecretory therapy in these patients remains controversial. The current study was designed to determine whether post-operative antise...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1993.tb00095.x

    authors： Metz DC,Benya RV,Fishbeyn VA,Pisegna JR,Orbuch M,Strader DB,Norton JA,Jensen RT

    更新日期：1993-06-01 00:00:00

  • Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

    abstract：BACKGROUND:Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM:To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METH...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15245

    authors： Scheiner B,Kirstein MM,Hucke F,Finkelmeier F,Schulze K,von Felden J,Koch S,Schwabl P,Hinrichs JB,Waneck F,Waidmann O,Reiberger T,Müller C,Sieghart W,Trauner M,Weinmann A,Wege H,Trojan J,Peck-Radosavljevic M,Vogel A

    更新日期：2019-05-01 00:00:00

  • Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.

    abstract：BACKGROUND:Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. AIMS:To meta-analyse endoscopic and histologic placebo response and remission rates in UC r...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/apt.14672

    authors： Ma C,Guizzetti L,Panaccione R,Fedorak RN,Pai RK,Parker CE,Nguyen TM,Khanna R,Vande Casteele N,D'Haens G,Sandborn WJ,Feagan BG,Jairath V

    更新日期：2018-06-01 00:00:00

  • Review article: can post-operative recurrence in Crohn's disease be prevented?

    abstract：:The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03055.x

    authors： Lémann M

    更新日期：2006-10-01 00:00:00

  • Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.

    abstract：BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.15687

    authors： Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

    更新日期：2020-05-01 00:00:00

  • Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer.

    abstract：AIM:To evaluate (i) the diagnostic usefulness of a delayed test in initially negative patients; and (ii) the reliability of the rapid urease test, histology or a combination of the two to diagnose Helicobacter pylori during emergency endoscopy in a large clinical practice series. PATIENTS AND METHODS:Records of patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.02726.x

    authors： Güell M,Artigau E,Esteve V,Sánchez-Delgado J,Junquera F,Calvet X

    更新日期：2006-01-01 00:00:00

  • Review article: transcriptional events controlling the terminal differentiation of intestinal endocrine cells.

    abstract：:Secretin-producing enteroendocrine cells arise from a multipotential endocrine progenitor in the crypts of the small intestine. As these cells migrate up the crypt-villus axis, they produce secretin and stop dividing as they terminally differentiate and die. Transcription of the secretin gene is controlled by a comple...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2000.014s1170.x

    authors： Mutoh H,Ratineau C,Ray S,Leiter AB

    更新日期：2000-04-01 00:00:00

  • Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

    abstract：AIM:To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study. METHODS:Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Int...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2002.01292.x

    authors： Warrington S,Baisley K,Boyce M,Tejura B,Morocutti A,Miller N

    更新日期：2002-07-01 00:00:00